PHARMA LITERATI

Colorcon Inc . and The Dow Chemical Company announced an agreement to broaden the existing Controlled Release Alliance between the two companies. While the Alliance currently provide controlled release technologies from Dow Pharma & Food Solutions, a business unit of Dow, to customers, effective January 1, 2017, it will be extended to include Dow’s advanced technology based pharmaceutical excipients. The Alliance has served the needs of the pharmaceutical industry, since announced in July 2007, providing customized solutions, products and support services for pharmaceutical product development. The addition of new technologies into the Alliance product portfolio expands the existing relationship between Colorcon and Dow and further enables formulation and development of fast-growing pharmaceutical applications, beyond the existing controlled release scope. “ This new phase reaffirms the long-standing commitment between the two companies to grow together and leverage the...

This guest-post is by Ishwor Poudel.  Whenever a new drug moiety is discovered or prepared along with the successful set of preclinical and clinical trials  and is further intended to be marketed, it need to go through a series of preformulation studies,  compatibility tests and the  precise formulation strategy. Active medicinal component alone only can’t be adequate enough to design a dosage form.  It’s where the excipients or additives come to play the role. Excipients can be defined as a non reactive ingredient added in the formulation in order to achieve the stability and the robust aestheticism in a drug. While going through a medicine, we only glance at the active ingredient but there are lot more beyond that while a drug is designed. I just intend to give a brief bird eye view over what additives really mean in the formulation and about proper surveillance over the quality of such components as an essential requisite. There is one normal miscon...